| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IGHA2 |
| Uniprot No | P01877 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-477aa |
| 氨基酸序列 | MKHLWFFLLLVAAPRWVLSQVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQTAGKGLEWIGYISHSGSTTYNPSLKSRVTLSLDTSKNQFSLRLNSVTAADTAVYYCAHGSSWDFAFDYWGQGTLVTVSSASPTSPKVFPLSLDSTPQDGNVVVACLVQGFFPQEPLSVTWSESGQNVTARNFPPSQDASGDLYTTSSQLTLPATQCPDGKSVTCHVKHYTNPSQDVTVPCPVPPPPPCCHPRLSLHRPALEDLLLGSEANLTCTLTGLRDASGATFTWTPSSGKSAVQGPPERDLCGCYSVSSVLPGCAQPWNHGETFTCTAAHPELKTPLTANITKSGNTFRPEVHLLPPPSEELALNELVTLTCLARGFSPKDVLVRWLQGSQELPREKYLTWASRQEPSQGTTTFAVTSILRVAAEDWKKGDTFSCMVGHEALPLAFTQKTIDRLAGKPTHVNVSVVMAEVDGTCY |
| 分子量 | 78 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人IGHA2蛋白的示例参考文献条目(部分为模拟示例，具体文献需根据实际研究补充)：
---
1. **《High-yield production of recombinant human IGHA2 in mammalian cell systems》**
- 作者：J. Smith et al.
- 摘要：研究通过优化哺乳动物细胞表达系统(如CHO细胞)，成功实现了重组人IGHA2的高效分泌表达，并验证其糖基化修饰与天然蛋白的一致性，为大规模生产奠定了基础。
2. **《Structural insights into IGHA2-FcαRI binding using cryo-EM》**
- 作者：L. Chen & M. Alvarez
- 摘要：通过冷冻电镜技术解析重组人IGHA2与其受体FcαRI的复合物结构，揭示了IGHA2铰链区构象变化对病原体中和作用的关键影响。
3. **《Recombinant IGHA2 as a mucosal adjuvant in antiviral therapy》**
- 作者：R. Gupta et al.
- 摘要：评估重组IGHA2在呼吸道合胞病毒(RSV)感染模型中的治疗效果，证明其通过增强黏膜免疫应答显著降低病毒载量。
4. **《Comparative analysis of IgA1 and IgA2 in pathogen neutralization》**
- 作者：K. Müller et al.
- 摘要：研究对比重组IgA1和IgA2对肠道致病菌的中和能力，发现IGHA2因铰链区稳定性在胃酸环境中更具优势。
---
*注：以上为假设性示例，实际文献需通过数据库(如PubMed、Web of Science)检索确认。建议使用关键词“recombinant IGHA2”“IgA2 expression”“human immunoglobulin A2”进行查询。*
**Background of Recombinant Human IGHA2 Protein**
The recombinant human IGHA2 protein is a biologically engineered form of the immunoglobulin alpha heavy chain 2 (IGHA2), a critical component of immunoglobulin A (IgA), the second most abundant antibody class in humans. IgA plays a pivotal role in mucosal immunity, protecting epithelial surfaces in the respiratory, gastrointestinal, and urogenital tracts. IgA exists in two subclasses, IgA1 and IgA2. with IGHA2 representing the heavy chain of the IgA2 subtype. IgA2 is distinct from IgA1 in its hinge region structure, carbohydrate content, and resistance to bacterial proteases, making it particularly important in combating pathogens in protease-rich environments.
Recombinant IGHA2 is produced using expression systems like mammalian cells (e.g., CHO or HEK293) to ensure proper post-translational modifications, including glycosylation, which is essential for functional stability and interactions with receptors like FcαRI. The recombinant protein typically retains key domains, such as the constant regions (CH1–CH3), enabling studies on IgA2’s effector functions, receptor binding, and immune modulation.
This protein is widely utilized in biomedical research to investigate IgA-mediated immune responses, host-pathogen interactions, and autoimmune disorders. Its recombinant form offers consistency, scalability, and reduced batch variability compared to native sources, facilitating therapeutic development for infections, cancers, or mucosal vaccine design. Additionally, it serves as a tool for structural studies and diagnostics targeting IgA-related pathologies.
×
